Nuvectis (NVCT) - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization

Graphic logo of Nuvectis (NVCT)

The EV/EBITDA price history for Nuvectis Pharma, Inc. (NVCT), which currently stands at 0.00, demonstrates the valuation of a business generating profit from exclusive rights to anti-cancer agents. Nuvectis Pharma, Inc. (NVCT) is implementing environmental standards in its laboratories and strictly adhering to bioethics. Management is currently focused on accelerating clinical trials for new molecules and seeking major partners among global pharmaceutical behemoths.

NVCT Nuvectis Pharma Inc.: Enterprise Value to Operating Income Before Depreciation in the range 11/23/2025 - 11/14/2026

NVCT (nuvectis.com): analytical breakdowns and indicator data

- stock price and consensus target price:
Stock Quotes Nuvectis|NVCT - Fair Value Consensus
- market capitalization indicators:
Market Value Nuvectis Pharma, Inc|NVCT - Total Enterprise Value
- book value of equity indicators:
Net Assets per Single Share Nuvectis Pharma|NVCT - Accounting Capitalization|Market Capitalization to Book Value Ratio nuvectis.com|NVCT - Cumulative Company Assets
- debt and liquidity data:
Debt to Equity Nuvectis Pharma, Inc.|NVCT - Long-Term Liabilities to Capital|Short-Term Debt to Equity Nuvectis Pharma|NVCT - Company Debts|Debt to Book Capitalization Ratio Nuvectis Pharma, Inc|NVCT - Long-Term Debt|Company Short-Term Debts Nuvectis Pharma|Quick Liquidity Indicator nuvectis.com
- business earnings and investment ratios data:
NVCT - Company Net Income|Future Profit Nuvectis Pharma, Inc.|NVCT - Company Value to Net Income|Projected Price to Earnings Nuvectis Pharma, Inc.|NVCT - Company Value to Earnings Growth Ratio|EV/EBITDA Multiple Nuvectis Pharma, Inc|NVCT - Income before deduction of interest, taxes and amortization|Net earnings per share (EPS TTM) Nuvectis Pharma|NVCT - Net earnings per one share for the last twelve months|Year-over-year earnings per share growth for the last twelve months nuvectis.com|NVCT - Earnings per share increase in current year|Earnings growth forecast for next year Nuvectis Pharma, Inc.
- sales and revenue indicators:
NVCT - Revenue and Sales Volume|Company Projected Revenue Nuvectis|NVCT - Price-to-Sales Ratio|Forward Price-to-Revenue Multiple Nuvectis Pharma, Inc
Summary company analytics:NVCT (Nuvectis)
Original product of Nuvectis Pharma

Nuvectis Pharma, Inc. (NVCT) monetizes a unique HSF1 suppression mechanism, ensuring significant pricing power within the resistant oncology segment. The calculated metric combines market capitalization and net debt, benchmarking them against EBITDA. This metric allows for an assessment of the business's real value, stripped of debt burdens and fiscal distortions. Analyzing the EV/EBITDA multiple, accounting for net debt, helps identify phases of asset overheating or undervaluation.

Competitor analysis

Incyte Corp. - Enterprise Value to EBITDA Ratio|Business Value to Operating Income Before Depreciation HCM|NUVB - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Company Value to EBITDA dayonebio.com|Monopar Therapeutics Inc. (MNPR) - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Enterprise Value to Operating Income Before Depreciation INBX|IMAB (I-Mab Biopharma Co., Ltd.) - EV/EBITDA Multiple|Enterprise Value to EBITDA Ratio Fennec (FENC)|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Heron Therapeutics (HRTX)|CHRS - Company Value to EBITDA|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Corbus Pharmaceuticals Holdings CRBP|Cardiff Oncology Inc. - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|BYSI - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Company Value to EBITDA BioAtla, Inc.|LIXT: EV/EBITDA Multiple|Enterprise Value to EBITDA Multiple Citius Pharmaceuticals, Inc. CTXR|Enterprise Value to EBITDA Ratio CLRB|Company Value to EBITDA BioLineRx Ltd BLRX|Enterprise Value to EBITDA Ratio CANF (Can-Fite BioPharma, Ltd.)|APRE (aprea.com) - Business Value to Operating Income Before Depreciation|Kazia Therapeutics Limited - Enterprise Value to EBITDA Ratio|Enterprise Value to Operating Income Before Depreciation Ratio SLXN (Silexion Therapeutics Corp.)|NuCana Corp - EV/EBITDA Multiple|Business Value to Operating Income Before Depreciation CMRX (Chimerix Inc.)|CYCC: EV/EBITDA Multiple|Company Value to EBITDA G1 Therapeutics (GTHX)|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Kronos Bio, Inc.|KTRA: Business Value to Operating Income Before Depreciation|EV/EBITDA Multiple ONCT|EV/EBITDA Multiple Portage Biotech Inc (PRTG)